PeptMentor
CalculatorsHow we source
PeptMentor
PeptMentor
Peptides
Eloralintide
Retatrutide
GHK-Cu
Pinealon
KPV
KLOW
All peptides
Compared
Eloralintide vs cagrilintide
Eloralintide vs retatrutide
Retatrutide vs tirzepatide
Guides and tools
Bac water for peptides
How to reconstitute peptides
Peptide reconstitution calculator
All guides
About
How we source
About
Editorial policy
Open the peptide calculator
PeptMentor

Plain answers about peptides and GLP-1 medicines. Every figure links to its source and says what kind of study it came from.

No dose advice. No sponsors, sellers or affiliate codes.

Peptides

  • Eloralintide
  • GHK-Cu
  • KLOW
  • KPV
  • Pinealon
  • Retatrutide
  • All peptides

Compare

  • Eloralintide vs cagrilintide
  • Eloralintide vs retatrutide
  • Retatrutide vs tirzepatide

Guides and tools

  • Peptide reconstitution calculator
  • Bac water for peptides
  • How to reconstitute peptides
  • All guides

About us

  • About
  • How we check facts
  • Editorial policy
  • Sources
  • Contact
© 2026 PeptMentor LLC. For information only, not medical advice. In an emergency call 911.
Medical disclaimerTermsPrivacyConsumer health data
  1. /Home
  2. /Peptides
  3. /KLOW

Four-peptide blend · never studied

KLOW peptide: blend and evidence

KLOW mixes four peptides in one vial, and nobody has ever studied the mix. Whether you are curious, starting, or already using it, here is what is known, what is not, and what helps.

A man doing a slow stretch on a yoga mat at home
StatusNot FDA approved
How sure is science?Blend never studied
What is in itGHK-Cu, BPC-157, TB-500, KPV
Studies of the blendNone found

Status as of November 17, 2026. For information only, not medical advice: read the medical disclaimer.

Where are you with KLOW?

Before you decide

Good place to start. Here is what we would want to know before deciding, in plain words.

Nobody has studied the blend

No study has tested KLOW. The closest one gave two of the four parts together to rats, and found no extra benefit over either part alone.

AnimalThe closest study →

Two parts have no human data

For TB-500 and KPV, the FDA found no data at all from people. BPC-157 has three small, poor-quality human studies, 30 people in all. GHK-Cu has small skin studies only.

RegulatorEvidence for each part →

It is not an approved drug

None of the four parts is FDA approved. Law-firm summaries say the 2026 HHS draft policy covers single-ingredient products only and leaves out GHK-Cu, so a four-part vial falls outside it.

Status and timeline →

Compete in sport?

KLOW holds BPC-157 and TB-500. WADA bans both at all times.

RegulatorSource: WADA Prohibited List[1]Drug testing in sport →

Take these questions to your doctor

  • Is there an approved treatment for my goal, with real trial data?
  • KLOW has never been studied. How would we know if it helps or harms me?
  • Could it affect my other medicines? No study has checked.
  • If I react, how would we tell which of the four parts caused it?
  • I compete in sport. Would this break anti-doping rules?

Coming Pick your questions and print them as one page.

Your first weeks

No judgement. Nobody has tested this combination in people, so there is no trial to say what to expect. Here is what still helps.

There is no KLOW dose

No study has tested KLOW in people, so there is no dose, schedule or cycle for it. Any dose question belongs with your doctor.

Questions to ask instead →

Check your own label

Labels differ between sellers: 80 mg, 90 mg or 40 mg in total, split in different ways. The amounts on a label are what is in the vial, not a dose. The calculator only turns those numbers into mg per mL.

Open the blend calculator →

Keep every step clean

If you mix a vial, use clean, careful technique. Nobody has published how long the mixed blend keeps or how to store it.

How to reconstitute peptides →

Write down your starting point

  • The full label: total mg, the split between the four parts, and the batch number.
  • What you hope will change, written down before you start.
What to note →

Living with it

You’re using it. Nobody has tested this four-part mix in people, so keep a close eye on how you feel and keep your doctor in the loop.

If you react, you can’t tell which part

If you get a rash or swelling, there is no way to tell which of the four parts caused it. And you cannot stop just one part while keeping the others.

Why a blend is hard to judge →

A possible immune reaction

For BPC-157, TB-500 and injected GHK-Cu, the FDA flags a possible immune reaction, meaning your body’s defences react to the peptide.

RegulatorSource: FDA: bulk substances that may present significant safety risks[2]

Is it working?

Notes like these help a doctor. They cannot tell you which part of the blend did what.

  • Give your goal a simple 0 to 10 score, on the same day each week.
  • Note any new symptom, such as a rash, swelling or pain, with the date.
  • Photograph any skin area you are watching, in the same light each time.
Tracking notes →

Reading up on single parts

Two of the four parts have their own pages: GHK-Cu and KPV. What they show is about each part alone, not the blend.

Got it online? Lower the risk.

No judgement. We won’t tell you where to buy or how much to take, but these steps lower the risk whatever you use:

  • Vials sold as “research use only” are not covered by any FDA list or by the HHS draft policy. Reviews raise concerns about what is really in such products, how pure and strong they are, and whether they are sterile.
  • Use clean technique every time. See how to reconstitute peptides.
  • Tell your doctor what you are taking, even if it feels awkward, and bring the vial label.
  • Learn the warning signs in “When to get help” before you need them.
  • Report a bad reaction to the FDA’s MedWatch. It helps everyone.
Source: FDA MedWatch[3]

When to get help

KLOW has no drug label, so there is no official list of warning signs for it. Here is what general allergy advice says, and when to call your doctor.

Emergency: call 911 (or your local emergency number). Possible overdose or wrong amount: Poison Help, 1-800-222-1222, free and open 24 hours. Report a bad reaction to the FDA through MedWatch.

Get emergency help now if you have

These are general signs of a severe allergic reaction, not a KLOW list. Call 911 or your local emergency number.

  • Trouble breathing, wheezing or high-pitched breathing sounds.
  • Swelling of your face, eyes or tongue, or trouble swallowing.
  • Chest tightness, dizziness, slurred speech or passing out.
Source: MedlinePlus: Anaphylaxis[4]

Call your doctor if

Bring the vial label, with the batch number.

  • You feel unwell after using it, in any way.
  • You notice a new rash, swelling or pain.
What is known about side effects →

Thinking of stopping?

No study has looked at stopping KLOW, so nobody knows what to expect. Talk it through with your doctor, and bring your notes.

Report a bad reaction

Tell the FDA’s MedWatch about any bad reaction. Reports help spot problems with products nobody has studied.

Source: FDA MedWatch[3]

The science, if you want it

Every number below says what kind of study it came from. Bracketed numbers point to the sources listed at the end.

No studies of the blendNot FDA approved
CellAnimalSmall humanHuman randomised trialApproved

Blend not studied

Facts checked 2026-11-17 · by PeptMentor Team · How we source

On this page
At a glanceWhat to expect over timeLiving with it day to day: why a blend is hard to judgeSide effects: what's known and when to get helpIs it working? How to track itYour appointment checklistWhat is KLOW?What's in KLOW: the evidence for each peptideHas KLOW itself been studied?Is KLOW legal? FDA and compounding statusKLOW and drug testing in sportKLOW dosage chart: what studies actually usedKLOW calculator and reconstitution: arithmetic onlySide effects reportedKLOW vs GLOW vs Wolverine, and separate vialsTrials to watchKLOW: questions people askSources

At a glance

Key takeaways
  • KLOW is four peptides in one vial. No study has tested the mix.
  • None of the four parts is an approved drug.
  • For two parts, TB-500 and KPV, FDA found no data at all from people.RegulatorFDA: bulk substances that may present significant safety risks[2]
  • If something happens on a four-part mix, you cannot tell which part caused it.
  • Two parts, BPC-157 and TB-500, are banned in sport at all times.RegulatorWADA Prohibited List[1]
I'm…New to itWorried about a side effectDoing the vial mathsComparing blendsCompeting in sport

What to expect over time

No study has followed people taking KLOW, so there is no week-by-week picture from trials. Any KLOW timeline you see online has no study behind it.

Living with it day to day: why a blend is hard to judge

One vial, four unknowns. If you feel better, you cannot tell which part helped. If you get a rash or swelling, you cannot tell which part caused it. And you cannot stop just one part while keeping the others.

Two parts together did no better in rats. In 32 rats with a repaired heel tendon, BPC-157 and TB-500 together gave no extra benefit over either one alone (animal study)[5].

Labels differ. The most common label we saw reads 80 mg in total, of which 50 mg is GHK-Cu. Others read 90 mg with no split, or 40 mg split evenly four ways. So two KLOW vials may not hold the same thing.

Storage is unknown. There is no label for KLOW. We found no published data on how long the mixed blend keeps or how to store it once mixed.

What is known about each part, in plain words:

  • BPC-157: three small human studies, 30 people in all, judged very low quality[6].
  • TB-500: no human data, per FDA. Trials of a longer, related protein (thymosin beta-4) do not count for it[2][7].
  • GHK-Cu: small skin studies only, some with no benefit. Never tested as a shot. See the GHK-Cu page.
  • KPV: cells and mice only. Never given to people in a study[2]. See the KPV page.

Side effects: what's known and when to get help

No study of KLOW exists, so no one knows how often side effects happen. For TB-500 and KPV there are no human safety data at all. For BPC-157, TB-500 and injected GHK-Cu, FDA flags a possible immune reaction, meaning your body's defences react to the peptide[2].

KLOW and its parts have no drug label, so we do not make up a KLOW-specific list of warning signs. The general allergy signs in “Something feels off” at the top of this page come from MedlinePlus and apply to any product. If you feel unwell after any product, talk to a doctor or pharmacist and bring the vial label.

Is it working? How to track it

Notes worth keeping if you already use it
  • The full label: total mg, the split between the four parts, and the batch number.
  • What you hope will change, written down before you start.
  • A simple score for that goal, such as 0 to 10, on the same day each week.
  • Any new symptom, such as a rash, swelling or pain, with the date.
  • Photos of any skin area you are watching, in the same light each time.

Notes like these help a doctor. They cannot tell you which part of the blend did what.

Your appointment checklist

Bring these to your appointment
  • Is there an approved treatment for my goal, with real trial data?
  • KLOW has never been studied. How would we know if it helps or harms me?
  • Could it affect my other medicines? No study has checked.
  • If I react, how would we tell which of the four parts caused it?
  • Does a four-part vial fall under any FDA or HHS policy?
  • I compete in sport. Would this break anti-doping rules?

Any dose question belongs here. No KLOW dose has been studied, so there is no trial figure to point to.

What is KLOW?

Where the name comes from and what labels say.
KLOW in short

What it is: a seller and forum name for a vial holding GHK-Cu, BPC-157, TB-500 and KPV. The blend itself has never been studied. Status: none of the four parts is FDA approved, and a four-ingredient vial is outside the HHS draft policy published 2026-10-30[8]. Evidence: blend, none; parts, from small human studies to cell only.

0

Published or registered studies of the KLOW blend (searched 2026-11-17)[9]

Trial registry
n = 30

All human BPC-157 data in a 2026 systematic review, across 3 small studies[6]

Small human study
0

Human exposure data FDA found for TB-500 or KPV[2]

Regulator
Best evidence so far
CellAnimalSmall humanHuman randomised trialApproved

Blend not studied

The blend has no study at any level. Its parts range from small human studies (BPC-157, topical GHK-Cu) to animal only (TB-500) and cell and animal only (KPV).

Where the name comes from. On forums and seller pages, KLOW is read as "GLOW" (GHK-Cu, BPC-157 and TB-500) plus KPV. This is marketing usage. We found no developer, company, patent or first publication for the name.

What a typical vial label says. The most common seller label we saw (2026-11-17) reads 80 mg in total: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. We do not link sellers.

Labels vary between sellers. Other labels we saw read 90 mg with no split given, or 40 mg split evenly four ways. Any arithmetic has to start from the numbers on your own label.

What's in KLOW: the evidence for each peptide

The evidence for each of the four peptides.

Sellers describe KLOW as being used for healing, skin and inflammation. The table shows how far the evidence for each part actually goes. None of it tests the blend.

PartWhat it isBest human evidenceStudy typePage
BPC-157Synthetic 15-amino-acid peptide[10]3 small studies, n = 30 in total, judged very low certainty[6]Small human studyNot yet on this site
TB-500Seven-amino-acid fragment of thymosin beta-4, LKKTETQ[2]None: FDA found no human exposure data[2]AnimalNot yet on this site
GHK-CuCopper-bound tripeptide[11]Small topical trials; no injection study[12]Small human study (topical only)GHK-Cu
KPVTripeptide Lys-Pro-Val from alpha-MSH[13]None: FDA found no human exposure data[2]Cell and animalKPV

BPC-157. A 2026 systematic review found three small human studies with 30 people in total, all of poor quality[6]. They are a phone survey of 16 knee-pain patients at one clinic, 14 of whom reported relief, with no control group[14]; 12 women with interstitial cystitis given one 10 mg injection into the bladder wall, 10 of whom reported full resolution[15]; and a 2-person IV safety report[16].

TB-500 (not the same as thymosin beta-4). FDA has not identified any human exposure data for the TB-500 fragment[2]. A 2026 orthopaedic review stresses that TB-500 is a distinct short fragment with no proven equivalence to full-length thymosin beta-4[7]. The human trials of full-length thymosin beta-4, such as a 40-person IV phase 1[17], therefore say nothing direct about TB-500.

GHK-Cu. The human studies are small and topical, and some were negative. No study has tested injected GHK-Cu. See the GHK-Cu page for every trial.

KPV. KPV has been studied only in cells and animals, mainly mouse colitis models[18][13]. FDA found no human exposure data[2]. See the KPV page.

Has KLOW itself been studied?

The closest study: two parts together, in rats.

No. The closest study tested two of the four parts together in rats. In 32 rats with Achilles tendon repairs, BPC-157 and TB-500 given together brought no extra benefit over either one alone (animal study)[5]. There are no data on whether KLOW works or how long it might take.

Is KLOW legal? FDA and compounding status

Dated FDA and HHS status for each part.

None of the four parts is an FDA-approved drug, and no KLOW product is approved. Before April 2026 all four sat in FDA's category 2 of bulk substances that may present significant safety risks. FDA's reasons were possible immune reactions (BPC-157, TB-500, GHK-Cu), no human exposure data (KPV, TB-500) and limited human data (GHK-Cu)[2].

  1. 2026-02-27

    The HHS Secretary says about 14 peptides will be made more accessible.

    Frier Levitt summary[19] Regulator
  2. 2026-04-15

    BPC-157, TB-500, KPV and injectable GHK-Cu leave FDA category 2 because their nominators withdrew them. Leaving the list does not make them legal to compound.

    Frier Levitt summary of the FDA notice[19] Regulator
  3. 2026-04-22

    FDA's safety page lists all four parts under "nominated but withdrawn".

    FDA safety-risk page[2] Regulator
  4. 2026-07-23

    FDA advisory committee votes 8-6-1 to recommend BPC-157, KPV and TB-500 for the 503A list. The vote is advisory; FDA staff had recommended against.

    McDermott summary of the meeting[20] Regulator
  5. 2026-10-30

    HHS publishes a draft enforcement-discretion policy for compounding certain peptides. Law-firm summaries of its Appendix A list BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, as single-ingredient products only, with limited routes. GHK-Cu is not covered.

    Federal Register 91 FR 68526; McDermott summary of Appendix A[8] Regulator
  6. By end of Feb 2027

    Planned separate FDA advisory committee review of injectable GHK-Cu.

    FDA 503A nominated substances list[21] Regulator

Why a KLOW blend falls outside the 2026 HHS policy. The policy is a draft. According to law-firm summaries of its Appendix A, it covers only products with a single active ingredient, and it does not include GHK-Cu[22]. A four-peptide vial with GHK-Cu fails on both counts. We have not been able to read the appendix itself, and we will update this section if a final version is issued.

Research-use-only vials. Vials sold as "research use only" are not covered by any FDA list or by the HHS draft policy. We found no FDA warning letter or import alert naming KLOW (searched 2026-11-17).

KLOW and drug testing in sport

WADA status of each part.

Two of the four parts are named on the WADA Prohibited List[1]. A KLOW vial contains both.

PartWADA 2026 Prohibited ListSource
BPC-157Named under S0 (non-approved substances); banned at all timesWADA[1]
TB-500Named under S2.3 (thymosin beta-4 and its derivatives); banned at all timesWADA[1]
GHK-CuNot named; the S0 catch-all probably appliesWADA[1]
KPVNot named; the S0 catch-all probably appliesWADA[1]

KLOW dosage chart: what studies actually used

What single-part studies used. Not KLOW doses.
There is no KLOW dose
No human study has tested KLOW. There is no published dose, frequency or cycle for the blend. The table below lists what studies of single parts used. These are not KLOW doses, and animal amounts are not converted.
PartStudyAmount as publishedRouteHow longStudy type
BPC-157Interstitial cystitis, n = 12[15]10 mg total, one procedureInjection into bladder wallOnceSmall human study
BPC-157IV safety report, n = 2[16]10 mg day 1, 20 mg day 2IV2 daysSmall human study
BPC-157Oral phase 1, no results posted[23]1, 3 or 6 mg single; 3 mg every 8 h; placeboOral tabletSingle dose or 2 weeksTrial registry
TB-500No human dose published[2]NoneNoneNoneRegulator
Thymosin beta-4, full length (not TB-500)Phase 1, n = 40[17]42, 140, 420 or 1260 mg daily vs placeboIV14 daysHuman RCT
GHK-CuNo injected human dose publishedNoneNoneNoneNone
GHK-CuOngoing wound trial[24]0.1% gel once dailyTopical14 daysTrial registry
KPVNo human dose[2]NoneNoneNoneRegulator
BPC-157 + TB-500Rat Achilles repair, n = 32[5]BPC-157 10 µg/kg/day; TB-500 60 µg/kg/dayIntraperitoneal4 weeksAnimal

Not KLOW doses. Single-part studies only; animal amounts not converted.

Searches for a KLOW "dosage chart", "dose per day", "frequency" or "cycle" all have the same answer: none of these exists for the blend.

KLOW calculator and reconstitution: arithmetic only

No human dose of KLOW has been studied
The figures below only turn the milligrams on a label into milligrams per mL. They do not suggest an amount to draw.

Before you use the calculator

  • It does arithmetic on the numbers you type from your own label. It does not suggest an amount or say whether anything is safe for you.
  • It is not medical advice. Check every result with your pharmacist or prescriber before you use it.
  • Its units are for U-100 insulin syringes only (the box or barrel says U-100).
  • In an emergency call 911. For a possible overdose call Poison Help at 1-800-222-1222.

Your answer is saved only in this browser so you are not asked again. See the privacy policy.

Arithmetic only. Change the part sizes to match your own label; seller labels differ. For one peptide per vial, use the reconstitution calculator.

Adding water changes concentration, not the amount of peptide in the vial. For an 80 mg label split 50/10/10/10 mg (the common seller label described above):

Water addedTotalGHK-CuBPC-157TB-500KPV
2 mL40 mg/mL25 mg/mL5 mg/mL5 mg/mL5 mg/mL
3 mL26.7 mg/mL16.7 mg/mL3.3 mg/mL3.3 mg/mL3.3 mg/mL

Arithmetic from the label: mg in the vial divided by mL of water. Not a dose.

For the mixing steps, see how to reconstitute peptides and BAC water for peptides. We found no published stability data for the mixed blend, so there is no evidence on how long it keeps or how it should be stored once mixed.

Side effects reported

What is known about side effects, part by part.
PartWhat is knownSourceStudy type
KLOW blendNo study, so no side-effect ratesPubMed and ClinicalTrials.gov search, 2026-11-17Trial registry
BPC-157No treatment-related adverse events reported in 30 people, but the studies were uncontrolled and poor quality, so this is not a safety finding[6]Small human study
TB-500No human safety data; FDA flags possible immune reactions from clumpingFDA[2]Regulator
Thymosin beta-4, full length (not TB-500)Adverse events "infrequent, and mild or moderate" in a 40-person IV phase 1[17]Human RCT
GHK-Cu, injectedFDA flags possible immune reactions from clumping and impurities; limited human dataFDA[2]Regulator
KPVNo human exposure dataFDA[2]Regulator
Commercial productsConcerns about identity, purity, concentration and sterility[7]Review

Reports online of swelling or "more inflammation" after starting KLOW have no published source, so we do not repeat them as findings.

KLOW vs GLOW vs Wolverine, and separate vials

NameGHK-CuBPC-157TB-500KPV
KLOWYesYesYesYes
GLOWYesYesYesNo
WolverineNoYesYesNo

Seller and forum names. None of these blends has been studied.

Separate vials vs one blend. No human study compares them. In rats, BPC-157 and TB-500 together gave no extra benefit over either alone[5]. Per law-firm summaries of the HHS draft policy, only single-ingredient products are covered, and GHK-Cu is not covered in any form[22].

There is no head-to-head data on KLOW against GHK-Cu alone. We found no interaction study of KLOW with retatrutide, naproxen, NAD or AOD-9604.

Trials to watch

Registered trials of single parts.

No trial of the blend is registered. These trials test single parts. The registry entries do not show doses for the first three, and three of the five share one sponsor whose background we have not checked.

TrialWhat it testsPhasePlanned nStatus
[25]BPC-157 vs placebo, hamstring strain2120Recruiting
[26]BPC-157 vs saline after rotator cuff repair130Not yet recruiting
[27]TB-500 dose escalation, stable atherosclerosis1/280Recruiting
[24]Topical 0.1% GHK-Cu gel, skin wounds260Recruiting
[23]Oral BPC-157 safety, healthy volunteers142Unknown; no results posted

KLOW: questions people ask

Direct answers to what people search for. Bracketed numbers point to the sources at the end; the sections above have the detail.

What exactly is in KLOW?

Four peptides in one vial: GHK-Cu, BPC-157, TB-500 and KPV. The mix itself has never been studied.

What do people use KLOW for?

Sellers market it for healing, skin and inflammation. No study has tested the blend. Some of its parts have never been tested in people at all.

Is KLOW the same as GLOW?

Almost. GLOW is usually GHK-Cu, BPC-157 and TB-500. KLOW adds KPV. Neither blend has been studied.

Is KLOW an approved drug?

No. None of its four parts is an approved drug, and no KLOW product is approved[2].

Can my pharmacy make KLOW for me?

Not under the new draft rules. Law-firm summaries say the HHS draft from October 2026 covers only products with one active part, and leaves out GHK-Cu[22]. A four-part vial falls outside it.

I compete in sport. Can I use KLOW?

KLOW holds BPC-157 and TB-500. WADA bans both at all times[1].

How much KLOW should I take?

No one knows. No study has tested KLOW in people, so there is no dose, schedule or cycle for it. The dose table on this page lists what studies of single parts used.

Can I take KLOW with retatrutide?

There is no data. No study has tested KLOW or any of its parts with retatrutide.

Sources

  1. 1.WADA Prohibited List Regulator
  2. 2.FDA: bulk substances that may present significant safety risks Regulator
  3. 3.FDA MedWatch
  4. 4.MedlinePlus: Anaphylaxis
  5. 5.BPC-157 + TB-500 rat Achilles study (PMID 42542926) Animal
  6. 6.BPC-157 systematic review, n = 30 (PMID 42885452) Small human study
  7. 7.Tham 2026 orthopaedic review, TB-500 vs thymosin beta-4 (PMID 42937313) Small human study
  8. 8.HHS draft peptide policy, 91 FR 68526 Regulator
  9. 9.Published or registered studies of the KLOW blend (searched 2026-11-17)
  10. 10.PMID 40789979
  11. 11.PMID 29986520
  12. 12.PMID 39963574
  13. 13.KPV mouse colitis (PMID 18092346) Animal
  14. 14.BPC-157 knee pain survey (PMID 34324435) Small human study
  15. 15.BPC-157 interstitial cystitis pilot (PMID 39325560) Small human study
  16. 16.BPC-157 IV safety report (PMID 40131143) Small human study
  17. 17.Thymosin beta-4 IV phase 1 (PMID 20536472) Human randomised trial
  18. 18.KPV mouse colitis (PMID 18061177) Animal
  19. 19.Frier Levitt summary
  20. 20.McDermott summary of the PCAC meeting, 2026-07-27 Regulator
  21. 21.FDA 503A nominated substances list, 2026-05-14 Regulator
  22. 22.McDermott summary of the HHS policy appendix, 2026-11-02 Regulator
  23. 23.NCT02637284
  24. 24.NCT07437586
  25. 25.NCT07437547
  26. 26.NCT07803250
  27. 27.NCT07487363
On this pageAt a glanceWhat to expect over timeLiving with it day to day: why a blend is hard to judgeSide effects: what's known and when to get helpIs it working? How to track itYour appointment checklistWhat is KLOW?What's in KLOW: the evidence for each peptideHas KLOW itself been studied?Is KLOW legal? FDA and compounding statusKLOW and drug testing in sportKLOW dosage chart: what studies actually usedKLOW calculator and reconstitution: arithmetic onlySide effects reportedKLOW vs GLOW vs Wolverine, and separate vialsTrials to watchKLOW: questions people askSources